| Janeen Clark, | |
|
1000 Corporate Center Dr Ste 200, Morrow, GA 30260-4129 | |
| (770) 968-6464 | |
| Not Available |
| Full Name | Janeen Clark |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 1000 Corporate Center Dr Ste 200, Morrow, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780971556 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 005243 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar Cobb Hospital | Austell, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellstar Medical Group, Llc | 6709065402 | 1839 |
News Archive
Alabama's prison system, badly overcrowded and facing a lawsuit over medical treatment of inmates, is facing its worst outbreak of tuberculosis in five years, a health official said Thursday. Pam Barrett, director of tuberculosis control for the Alabama Department of Public Health, said medical officials have diagnosed nine active cases of the infectious respiratory disease in state prisons so far this year (8/14).
Research from The Cancer Institute of New Jersey shows that an ultra-shortened, accelerated breast irradiation treatment using a balloon device is both logistically achievable and tolerable. The work will be offered during a poster presentation at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium this week. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).
The National Institutes of Health today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at The Wistar Institute, was awarded the prestigious NIH Director's New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 5 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Alabama's prison system, badly overcrowded and facing a lawsuit over medical treatment of inmates, is facing its worst outbreak of tuberculosis in five years, a health official said Thursday. Pam Barrett, director of tuberculosis control for the Alabama Department of Public Health, said medical officials have diagnosed nine active cases of the infectious respiratory disease in state prisons so far this year (8/14).
Research from The Cancer Institute of New Jersey shows that an ultra-shortened, accelerated breast irradiation treatment using a balloon device is both logistically achievable and tolerable. The work will be offered during a poster presentation at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium this week. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).
The National Institutes of Health today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at The Wistar Institute, was awarded the prestigious NIH Director's New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janeen Clark, 1000 Corporate Center Dr Ste 200, Morrow, GA 30260-4129 Ph: () - | Janeen Clark, 1000 Corporate Center Dr Ste 200, Morrow, GA 30260-4129 Ph: (770) 968-6464 |
News Archive
Alabama's prison system, badly overcrowded and facing a lawsuit over medical treatment of inmates, is facing its worst outbreak of tuberculosis in five years, a health official said Thursday. Pam Barrett, director of tuberculosis control for the Alabama Department of Public Health, said medical officials have diagnosed nine active cases of the infectious respiratory disease in state prisons so far this year (8/14).
Research from The Cancer Institute of New Jersey shows that an ultra-shortened, accelerated breast irradiation treatment using a balloon device is both logistically achievable and tolerable. The work will be offered during a poster presentation at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium this week. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).
The National Institutes of Health today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at The Wistar Institute, was awarded the prestigious NIH Director's New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.
› Verified 5 days ago
Rana Botlani Esfahani, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1000 Corporate Center Dr, Ste 200, Morrow, GA 30260 Phone: 770-968-6464 | |
Alvin H Webster, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 6522 Peacock Blvd, Morrow, GA 30260 Phone: 678-778-4591 Fax: 770-961-0056 | |
Dr. Evelyn Campbell-bayaan, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1331 Mount Zion Rd, Morrow, GA 30260 Phone: 770-629-3217 | |
Rhonda R. Freeman, NP Family Medicine Medicare: Medicare Enrolled Practice Location: 2005 Mount Zion Rd, Morrow, GA 30260 Phone: 770-919-5250 | |
Dr. George W Brown Iv, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Corporate Center Dr, Ste 200, Morrow, GA 30260 Phone: 770-968-6464 Fax: 770-968-6455 | |
Dr. Mark Mcelhannon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Corporate Center Dr, Suite 200, Morrow, GA 30260 Phone: 770-968-6464 Fax: 770-968-6455 | |
Gabriella Eliese Maris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Corporate Center Dr, Suite 200, Morrow, GA 30260 Phone: 770-968-6464 Fax: 770-968-6455 |